Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP306 in Hyperphosphatemia on Hemodialysis
NCT06712654Phase 2Recruiting
- Sponsor
- R1 Therapeutics
- Start
- Jun 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of EOS789 in hyperphosphatemia (7 cohorts), sponsored by R1 Therapeutics. Primary endpoint: Ability of AP306 to lower serum phosphate at 8 weeks. Started Jun 2026; status: recruiting.
02
Drugs
EOS789
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT06712654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06712654.